Bright Minds Biosciences (DRUG) Receivables - Other (2022 - 2025)

Bright Minds Biosciences (DRUG) has 4 years of Receivables - Other data on file, last reported at $113645.2 in Q2 2025.

• Quarterly Receivables - Other changed N/A year-over-year to $113645.2 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $113645.2 (changed N/A YoY) and the FY2022 annual result came in at $31636.7, changed N/A from the prior year.
• Receivables - Other retreated to $113645.2 in Q2 2025, from $123994.7 in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $401891.4 in Q1 2024 to a low of $30397.1 in Q4 2022.
• A 4-year average of $108971.8 and a median of $31636.7 in 2022 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2024 — Receivables - Other surged 1216.79% — and 2025, when it tumbled 69.15%.
• Tracing DRUG's Receivables - Other over 4 years: stood at $30397.1 in 2022, then advanced by 1.05% to $30716.9 in 2023, then soared by 1208.37% to $401891.4 in 2024, then plunged by 71.72% to $113645.2 in 2025.
• The last three Receivables - Other figures came in at $113645.2 (Q2 2025), $123994.7 (Q1 2025), and $401891.4 (Q1 2024), per Business Quant data.